Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 4/20 | 0.43 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15356487 | 0.82 | MPL (0.50) | ALDH1A1L3MBTL1TDP1RAB9ASMN1; SMN2 | |
| SCHEMBL6415273 | 0.81 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1TDP1RAB9ASMN1; SMN2 | |
| SCHEMBL5895082 | 0.81 | ALDH1A1 (0.73) | ALDH1A1L3MBTL1TDP1RAB9ASMN1; SMN2 | |
| SCHEMBL4727339 | 0.81 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1TDP1SMN1; SMN2NUDT1 | |
| SCHEMBL8847516 | 0.80 | KDM4E (0.58) | HTR2BALDH1A1L3MBTL1TDP1RAB9A | |
| SCHEMBL104951 | 0.78 | KDM4E (0.58) | ALDH1A1L3MBTL1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL15356484 | 0.77 | SHMT2 (0.57) | ALDH1A1TDP1RAB9ACYP19A1PIM1 | |
| SCHEMBL1194033 | 0.76 | RAB9A (0.80) | HTR2BALDH1A1RAB9ACASP3SMN1; SMN2 | |
| SCHEMBL3047990 | 0.75 | HTR2B (0.49) | HTR2BALDH1A1L3MBTL1TDP1RAB9A | |
| SCHEMBL9830640 | 0.74 | HTR2B (0.60) | HTR2BALDH1A1L3MBTL1TDP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319017-A1 | OPEN-CELL FOAM BASED WOUND TREATMENT | SMITH SCOTT C (US) | 2025-10-16 | — | — | US | claimed |
| EP-4531940-A1 | OPEN-CELL FOAM BASED WOUND TREATMENT | Smith, Scott C. (US) | 2025-04-09 | — | — | EP | claimed |
| EP-4216966-B1 | FORMULATION BASED ON POLYHEXAMETHYLENE BIGUANIDE FOR USE IN THE TREATMENT OF ACANTHAMOEBA KERATITIS AND/OR FUNGAL INFECTIONS | SIFI SPA (IT) | 2024-11-13 | — | — | EP | claimed |
| WO-2023230285-A1 | OPEN-CELL FOAM BASED WOUND TREATMENT | SMITH SCOTT C (US) | 2023-11-30 | — | — | WO | claimed |
| WO-2026090608-A2 | PEPTIDE COMPOUNDS FOR TRAUMATIC BRAIN INJURY | The Government of the United States, as represented by the Director of the Defense Health Agency (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260021159-A1 | STABLE PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF MODERATE/SEVERE DRY EYE-RELATED OCULAR SYMPTOMS | TEARSOLUTIONS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260001997-A1 | SULFUR POLYMER | IDAHO STATE UNIV (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250319017-A1 | OPEN-CELL FOAM BASED WOUND TREATMENT | SMITH SCOTT C (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250222070-A1 | STABLE PEPTIDE COMPOSITIONS | TEARSOLUTIONS INC (US) | 2025-07-10 | — | — | US | disclosed |
| EP-4326353-B1 | ENHANCED ANTIMICROBIAL EFFICACY (SYNERGY) OF SILVER AND COPPER COMPOUNDS AND MEDICAL USE OF THEIR COMBINATIONS | NANORDICA MEDICAL OUE (EE) | 2025-06-18 | — | — | EP | disclosed |
| EP-4547221-A2 | STABLE PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF MODERATE/SEVERE DRY EYE-RELATED OCULAR SYMPTOMS | TearSolutions, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4531940-A1 | OPEN-CELL FOAM BASED WOUND TREATMENT | Smith, Scott C. (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-115650409-A | Photocatalysis-biological coupling denitrification and denitrification system and in-situ construction method thereof | 中国科学技术大学苏州高等研究院 | 2023-01-31 | — | — | CN | disclosed |
| EP-4095152-A2 | ENGINEERED RIBOSOMAL PROMOTERS FOR PROTEIN PRODUCTION IN MICROORGANISMS | Danisco US Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3419991-B1 | ENGINEERED RIBOSOMAL PROMOTERS FOR PROTEIN PRODUCTION IN MICROORGANISMS | DANISCO US INC (US) | 2022-10-26 | — | — | EP | disclosed |
| US-20220305083-A1 | STABLE PEPTIDE COMPOSITIONS | TEARSOLUTIONS INC (US) | 2022-09-29 | — | — | US | disclosed |
| US-11447782-B2 | Engineered ribosomal promoters for protein production in microorganisms | DANISCO US INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-3986914-A1 | CONSTRAINED PEPTIDES | TearSolutions, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20220105167-A1 | ESCHERICHIA COLI 0157:H7 PROTEINS AND USES THEREOF | Institut National de Recherche pour l'Agriculture, l'Alimentation et I'Environnement (FR) | 2022-04-07 | — | — | US | disclosed |
| EP-3632919-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2020-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021159-A1 | STABLE PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF MODERATE/SEVERE DRY EYE-RELATED OCULAR SYMPTOMS | TRPC1, TRPC7, ASNS | HTR2B 2632/4885ALDH1A1 4599/4885L3MBTL1 2028/4885 |
| US-20260001997-A1 | SULFUR POLYMER | STS, TST, CBS | HTR2B 1082/4885ALDH1A1 884/4885L3MBTL1 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.